Literature DB >> 32882157

Immunization status and re-immunization of childhood acute lymphoblastic leukemia survivors.

Ersin Toret1, Sumeyye Emel Yel1, Murat Suman1, Yeter Duzenli Kar1, Zeynep Canan Ozdemir1, Meltem Dinleyici2, Ozcan Bor1.   

Abstract

Intensive chemotherapy can cause long-lasting immunosuppression in children who survived cancer. The immunosuppression varies according to the type of cancer, intensity of chemotherapy and age of the patient. A sufficient immune reconstruction when has been completed in childhood cancer survivors, the re-vaccination program can achieve sufficient antibody levels for some of the life-threatening vaccine-preventable infectious diseases. This study evaluates the serological status of pediatric acute lymphoblastic leukemia (ALL) cases before and after the intensive chemotherapy treatment. Antibodies against measles, mumps, rubella, varicella, hepatitis A and B were tested with the enzyme-linked immunosorbent assay (ELISA) method. Antibody titers were measured firstly at the leukemia diagnosis time when the chemotherapy was not started. The second evaluation of antibody titers was studied at 6 months after the cessation of chemotherapy for all patients. Forty-six patients with the mean age of 6.1 ± 4.5 years were participated in this study. Changing to seronegative after treatment was significantly different in measles, rubella, hepatitis A and hepatitis B (p < .05). Seventy-eight (28%) antibody levels in the patients were non-protective for all diseases. Only three (7%) patients had protective antibody levels for all diseases in the sixth month of chemotherapy cessation. There was a negative correlation between patient's age and losing protective antibody levels for any vaccine-preventable disease (p < .05). Antibody levels against vaccine-preventable diseases have evident that reduced after ALL treatment at childhood. Pediatric ALL survivors must be re-vaccinated for vaccine-preventable diseases after achieving immune reconstruction.

Entities:  

Keywords:  Childhood; cancer; immunity; leukemia; survivors; vaccination

Year:  2020        PMID: 32882157      PMCID: PMC8018341          DOI: 10.1080/21645515.2020.1802975

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  17 in total

Review 1.  Leukemias in Children.

Authors:  Rachna Seth; Amitabh Singh
Journal:  Indian J Pediatr       Date:  2015-02-15       Impact factor: 1.967

2.  Childhood and adolescent cancer statistics, 2014.

Authors:  Elizabeth Ward; Carol DeSantis; Anthony Robbins; Betsy Kohler; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-31       Impact factor: 508.702

3.  Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia.

Authors:  Selin Aytac; S Songul Yalcin; Mualla Cetin; Sevgi Yetgin; Fatma Gumruk; Murat Tuncer; Kadriye Yurdakok; Aytemiz Gurgey
Journal:  Pediatr Hematol Oncol       Date:  2010-08       Impact factor: 1.969

4.  Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens.

Authors:  Anna Nilsson; Angelo De Milito; Pär Engström; Margareta Nordin; Mitsuo Narita; Lena Grillner; Francesca Chiodi; Olle Björk
Journal:  Pediatrics       Date:  2002-06       Impact factor: 7.124

5.  Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group.

Authors:  Torben Ek; Lotta Mellander; Bengt Andersson; Jonas Abrahamsson
Journal:  Pediatr Blood Cancer       Date:  2005-05       Impact factor: 3.167

6.  Survivors of childhood cancer: an Australian audit of vaccination status after treatment.

Authors:  Nigel W Crawford; John A Heath; David Ashley; Peter Downie; Jim P Buttery
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

7.  Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience.

Authors:  Nicola Santoro; Antonella Colombini; Daniela Silvestri; Massimo Grassi; Paola Giordano; Rosanna Parasole; Elena Barisone; Roberta Caruso; Valentino Conter; Maria G Valsecchi; Giuseppe Masera; Carmelo Rizzari
Journal:  J Pediatr Hematol Oncol       Date:  2013-07       Impact factor: 1.289

8.  Immunization status in childhood cancer survivors: A hidden risk which could be prevented.

Authors:  Najwa Yahya Fayea; Ashraf Elsayed Fouda; Shaimaa Mohamed Kandil
Journal:  Pediatr Neonatol       Date:  2016-07-26       Impact factor: 2.083

Review 9.  Guidelines on vaccinations in paediatric haematology and oncology patients.

Authors:  Simone Cesaro; Mareva Giacchino; Francesca Fioredda; Angelica Barone; Laura Battisti; Stefania Bezzio; Stefano Frenos; Raffaella De Santis; Susanna Livadiotti; Serena Marinello; Andrea Giulio Zanazzo; Désirée Caselli
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

10.  The Impact of Chemotherapy after Pediatric Malignancy on Humoral Immunity to Vaccine-Preventable Diseases.

Authors:  Chiara Garonzi; Rita Balter; Gloria Tridello; Anna Pegoraro; Manuela Pegoraro; Monia Pacenti; Novella Scattolo; Simone Cesaro
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-03-01       Impact factor: 2.576

View more
  1 in total

1.  Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program.

Authors:  Hayley Gans; Roy F Chemaly
Journal:  BMC Infect Dis       Date:  2021-01-11       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.